Interleukin-1β regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes

被引:131
作者
LaPointe, MC [1 ]
Isenovic, E [1 ]
机构
[1] Henry Ford Hosp, Hypertens & Vasc Res Div, Detroit, MI 48202 USA
关键词
prostaglandins; phospholipases; nitric oxide; cell signaling;
D O I
10.1161/01.HYP.33.1.276
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The genes encoding inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2, also known as prostaglandin-endoperoxide synthase-2) are induced in many types of cells in response to proinflammatory cytokines, We have previously shown that interleukin-1 beta (IL) stimulates iNOS and COX-2 mRNA in cardiac myocytes. Because IL has been shown to activate mitogen-activated protein kinase (MAPK) signaling pathways in many different cells, we tested whether the p42/44 and p38 MAPK pathways were involved in IL stimulation of iNOS and COX-2, using a specific inhibitor of p42/44 activation, PD98059 (PD), and the p38 inhibitor SB205380 (SB). Nitrites were measured using the Griess reagent, prostaglandin PGE(2) by an enzyme immunoassay, iNOS and COX-2 protein by Western blot analysis, and iNOS mRNA by Northern blot analysis: Tested separately, the p38 kinase and MAPK inhibitors partially reduced IL stimulation of nitrite, iNOS protein, and iNOS mRNA; used together, they completely abolished the effect of IL. SE and PD inhibited IL-stimulated COX-2 protein by 60% and 80%, respectively, and IL-stimulated COX-2 protein was totally prevented by the combination of inhibitors. PGE(2) production was inhibited more than 99% by either drug alone, suggesting a posttranslational effect on enzyme activity, To test whether this posttranslational effect involved the cytosolic phospholipase A(2) (cPLA(2)) isoform, Western blots were probed for cPLA(2) protein. Results indicated that IL stimulated cPLA(2) activity and synthesis, which was inhibited by SE but not PD, These data indicate that (1) IL induction of iNOS synthesis depends on both the p42/44 and p38 signaling pathways, acting primarily at the level of transcriptional regulation; and (2) IL regulation of COX-2 synthesis involves the p42/44 and p38 signaling pathways, with an additional level of regulation occurring posttranslationally, perhaps at the level of activation of the cPLA(2) isoform, which may be involved in intracellular signaling, as well as regulation of arachidonic acid release for COX-2 activity.
引用
收藏
页码:276 / 282
页数:7
相关论文
共 50 条
[1]  
Appleton I, 1996, Adv Pharmacol, V35, P27, DOI 10.1016/S1054-3589(08)60274-4
[2]   Functional coupling between secretory phospholipase A2 and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A2 [J].
Balsinde, J ;
Balboa, MA ;
Dennis, EA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :7951-7956
[3]  
Bhat NR, 1998, J NEUROSCI, V18, P1633
[4]   Phosphorylation and activation of cytosolic phospholipase A(2) by 38-kDa mitogen-activated protein kinase in collagen-stimulated human platelets [J].
BorschHaubold, AG ;
Kramer, RM ;
Watson, SP .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 245 (03) :751-759
[5]  
CHIARIELLO M, 1987, J PHARMACOL EXP THER, V241, P560
[6]  
DENNIS EA, 1994, J BIOL CHEM, V269, P13057
[7]   MOLECULAR MECHANISMS OF NITRIC-OXIDE REGULATION - POTENTIAL RELEVANCE TO CARDIOVASCULAR-DISEASE [J].
DINERMAN, JL ;
LOWENSTEIN, CJ ;
SNYDER, SH .
CIRCULATION RESEARCH, 1993, 73 (02) :217-222
[8]   MEKKs, GCKs, MLKs, PAKs, TAKs, and Tpls: Upstream regulators of the c-Jun amino-terminal kinases? [J].
Fanger, GR ;
Gerwins, P ;
Widmann, C ;
Jarpe, MB ;
Johnson, GL .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1997, 7 (01) :67-74
[9]   p38 mitogen-activated protein kinase down-regulates nitric oxide and up-regulates prostaglandin E(2) biosynthesis stimulated by interleukin-1 beta [J].
Guan, ZH ;
Baier, LD ;
Morrison, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (12) :8083-8089
[10]   EFFECTS OF INTERLEUKIN-1-BETA AND NITRIC-OXIDE ON CARDIAC MYOCYTES [J].
HARDING, P ;
CARRETERO, OA ;
LAPOINTE, MC .
HYPERTENSION, 1995, 25 (03) :421-430